Science Digest: Antibody-Drug Conjugates and the Rise of Smart Chemotherapy

Targeting antibodies, potent payloads, and smarter linker chemistry are turning chemotherapy from a blunt instrument into a precision-guided therapy.

The era of treatment that poisons healthy tissue alongside tumors is giving way to something far more deliberate. Team KC Laboratory Informatics Consultants Brinda Kamalia and Kristina Whittington cover how antibody-drug conjugates (ADCs) are moving cancer care towards precision at the molecular level.

---

What is an ADC: the design paradigm

Chemotherapy has always come with a hard trade-off. The drugs that kill cancer cells also hit healthy ones, which is why treatment so often means hair loss, nausea, and blood counts that crater. Antibody-drug conjugates, or ADCs, are the attempt to fix that trade-off at the molecular level. The idea traces back to Paul Ehrlich's "magic bullet": a therapy that seeks out the tumor and leaves the rest of the body alone. Today more than 20 ADCs are approved across different tumor types, and the design is often described as "smart chemotherapy."

Every ADC is built from three parts, each a distinct engineering problem.

The antibody is the targeting system. It is a monoclonal antibody chosen to recognize a protein sitting on the surface of cancer cells, ideally one that healthy tissue barely expresses. This is what steers the drug to the tumor.

The payload is the warhead. It is a cytotoxic molecule far too toxic to give to a patient on its own, which is exactly the point: it is only delivered where the antibody goes. Approved ADCs currently rely on a narrow set of payload mechanisms. Per Tubulis, those are tubulin inhibition, topoisomerase-1 inhibition, and DNA damage induction. Expanding beyond those three is one of the field's active frontiers.

The linker is the part that holds the other two together, and it does more work than its size suggests. A good linker keeps the payload firmly attached while the ADC travels through the bloodstream, then releases it once the antibody has docked at the tumor. Get this wrong and the toxin leaks early, poisoning healthy tissue. Linker chemistry has become one of the main levers for differentiating a next-generation ADC. Older designs used maleimide-thiol chemistry, which can shed payload in circulation. Newer approaches like phosphonamidate linkers hold the payload in place far longer, which we come back to in the toxicity section.

One number ties all of this together: the drug-to-antibody ratio, or DAR. DAR is the average number of payload molecules attached to each antibody. More payload per antibody can mean a more potent drug, but historically, loading too much caused ADCs to clump together and get cleared from the body too fast. A central goal of modern linker design is building stable, high-DAR ADCs (often DAR8) that still behave like a normal antibody in the bloodstream.

Modern platforms are chasing all three components at once: better targets, more diverse payloads, and stabler linkers that allow high, uniform DAR without wrecking the ADC's behavior in the body. The rest of this digest is really a tour of how far each of those levers has moved.

Timeline 

The story of antibody-drug conjugates (ADCs) spans over a century of molecular innovation, with each boom driven by solving a fundamental engineering bottleneck in targeted delivery. The foundational concept originated in the early 1900s with the "magic bullet" hypothesis, the idea of a therapeutic agent that could selectively eliminate diseased cells while sparing healthy tissue. However, turning this vision into clinical reality stalled for decades until the development of hybridoma technology in 1975, which enabled the reproducible production of monoclonal antibodies (mAbs) with the precise specificity needed to target tumor antigens.

The first true clinical engineering era unfolded during the 1980s and 1990s as researchers realized that simply attaching standard chemotherapeutics to mAbs was insufficient. This prompted three major breakthroughs: the design of stable yet selectively cleavable linkers that prevent premature payload release in circulation, the adoption of sub-nanomolar ultra-potent payloads (such as auristatins, maytansinoids, and calicheamicins) to ensure cytotoxicity despite low cell-surface antigen density, and the transition from immunogenic mouse antibodies to humanized constructs (Chari, 2016).

Over the last decade, the field has undergone a major renaissance focused on optimization and platform versatility. Random conjugation methods, which yielded heterogeneous mixtures with erratic pharmacokinetics, have largely given way to site-specific conjugation techniques that yield precise drug-to-antibody ratios (DAR) and superior safety profiles. Simultaneously, the payload repertoire has expanded beyond microtubule inhibitors to topoisomerase I inhibitors, DNA-damaging agents, immune agonists, and protein degraders, while machine learning and computational structural design now accelerate target selection and payload-linker matching before entering the wet lab (Lyon et al., 2015; Lambert & Morris, 2017).

Where do ADCs live in the Therapeutic Journey?

ADCs are moving in two directions at the same time: toward earlier lines of treatment, and toward a wider and more precise set of tumor targets.

Earlier in treatment →

For years, ADCs were reserved for patients who had already exhausted standard options. That is changing. In May 2026, the FDA approved Datroway (datopotamab deruxtecan) as a first-line treatment for metastatic triple-negative breast cancer in patients who are not candidates for immunotherapy. That is a meaningful shift, because roughly 70% of these patients do not qualify for immunotherapy and had little beyond chemotherapy to fall back on. In the TROPION-Breast02 trial, the ADC extended median overall survival to 23.7 months versus 18.7 for chemotherapy and produced responses in about 63% of patients versus 29%. Datroway targets a protein called TROP2, and its approval alongside Enhertu's move into first-line HER2 breast cancer shows ADCs starting to supplant chemotherapy rather than follow it.

Toward better targets →

The antibody is only as good as the protein it aims at, so target selection has become the strategic core of ADC development. The pattern to look for is a protein that is abundant on tumor cells and nearly absent on healthy ones. QLS5132, an investigational ADC presented at the American Association for Cancer Research (AACR) 2026 annual meeting for platinum-resistant ovarian cancer, targets CLDN6, a protein highly expressed in ovarian cancer cells but minimally expressed in healthy tissue. In a heavily pretreated group with few options, it produced an objective response rate above 50%.

The newest strategy uses target selection to go after drug resistance directly. Barcelona-based Ona Therapeutics raised $87 million to build ADCs against novel targets found on the treatment-resistant cells that drive relapse, aiming for tumor types where patients have run out of options, including hormone receptor-positive, HER2-negative breast cancer and colorectal cancer. The reasoning, in the words of CEO Valerie Vanhooren, is that hitting the cells responsible for resistance can produce a deeper, more durable response. Taken together, the field is expanding from a handful of validated targets like HER2 and TROP2 toward a much wider map of tumor-specific proteins.

Payload Evolution: "More Targeted" vs. "Just More"

The state of ADC science is experiencing a shift in payload philosophy: the field is rapidly moving from a reliance on simple "more payload" (high drug-to-antibody ratios or maximum cytotoxicity) to a sophisticated paradigm of "more targeted payload" (expanding the chemical space, utilizing catalytic modes of action, and tuning release mechanics).

Where clinical ADCs historically leaned on a narrow slice of sub-nanomolar microtubule or topoisomerase I inhibitors, recent advances are unlocking completely novel classes of drugs. A prime example of this chemical expansion comes from novel platform chemistry, such as Tubulis’s phosphoramidate-based Alco5 platform, which breaks long-standing synthetic barriers to stably conjugate aliphatic and aromatic hydroxyl-containing molecules. This allows researchers to venture far beyond classical cytotoxins into entirely new mechanisms like nucleoside analogues (e.g., gemcitabine) and elongation factor inhibitors, delivering them with exquisite stability and targeted cytosolic release.

At the same time, the field is embracing degrader-antibody conjugates (DACs) to fundamentally alter how payloads kill tumor cells. Rather than relying on traditional cell-cycle poisons that demand heavy cellular accumulation, partnerships like the one between C4 Therapeutics and Roche are pioneering the use of targeted protein degraders as ADC payloads. Because degraders operate via an event-driven, catalytic mechanism, destroying disease-causing proteins repeatedly rather than acting stoichiometry-by-stoichiometry, they offer a much wider therapeutic window and a powerful tool against drug-resistant tumors.

Concurrently, validated topoisomerase I payloads continue to rewrite standard-of-care frontlines when optimized for safety and dosing, as seen with datopotamab deruxtecan's landmark FDA approval in first-line metastatic triple-negative breast cancer. Taken together, today's payload evolution isn't just about loading more drug onto an antibody; it is about expanding the druggable payload universe and picking the exact catalytic or mechanistic tool that tumor biology demands.

The Therapeutic Window and Toxicity Challenges

The whole promise of an ADC is a wider therapeutic window, and it is worth being precise about what that means. The therapeutic window is the gap between the dose that treats the disease and the dose that starts causing serious harm. A wider window means a drug can be dosed high enough to work while staying safe. ADCs are designed to widen this window by concentrating the toxic payload at the tumor instead of throughout the body, but doing that reliably is still the central engineering challenge.

In practice, three issues decide how wide that window actually is.

Linker stability →

If the linker releases its payload too early, free toxin circulates through the body and the window narrows right back toward ordinary chemotherapy. This is where linker chemistry earns its keep. Work on phosphonamidate-linked ADCs showed that a more stable linkage kept a high-DAR ADC intact in circulation for weeks, compared with older maleimide chemistry that sheds payload in serum. More stable attachment means less off-target toxicity, which is the same reason Tubulis frames its stable-linker work as a way to widen the therapeutic window by reducing toxicity while maintaining efficacy.

The bystander effect →

Once a payload is released inside a tumor, it can diffuse into neighboring cells and kill them too, even ones with little or none of the target protein. This cuts both ways. It helps against tumors where target expression is patchy: QLS5132 produced responses in ovarian cancer patients with no detectable CLDN6 expression, likely thanks to a bystander effect. But the same diffusion can spill into healthy tissue, so it is an efficacy tool and a toxicity risk at the same time.

Characteristic toxicities →

Even well-designed ADCs carry recognizable side-effect profiles. Datroway's trial reported mostly low-grade stomatitis, nausea, and alopecia. QLS5132's most serious side effects were largely hematologic. And a known concern with deruxtecan-class payloads is interstitial lung disease, which is exactly why it was notable that QLS5132 reported no cases of it, along with no ocular toxicity or febrile neutropenia at its recommended dose.

The through-line is that widening the window is not one fix but three moving parts working together: stable linkers that keep the payload where it belongs, new payloads and mechanisms that can overcome resistance without simply piling on toxicity, and disciplined target selection so the antibody rarely visits healthy tissue in the first place. Each of the ADCs above is an experiment in balancing those three, and the balance is what separates a promising molecule from an approved one.

Industry Trends 

On the business front, the ADC sector has shifted from speculative platform deals to aggressive mega-scale M&A, platform consolidation, and "first-in-class" commercial races as Big Pharma competes to secure market leadership in precision oncology. Big Pharma is no longer content simply licensing single assets; major players are spending billions to internalize next-generation conjugation chemistry and platform engines, as highlighted by Gilead Sciences’ acquisition of Tubulis for $3.15 billion upfront and up to $1.85 billion in biobuck milestones. By acquiring Tubulis, Gilead did not just grab late-stage clinical assets like TUB-040 (targeting NaPi2b in ovarian cancer); they secured Tubulis’ entire platform ecosystem, including the Alco5 and Tubutecan technologies, to establish a dedicated ADC Innovation Center in Munich.

At the same time, pharma giants are leveraging heavily structured biobuck partnerships to de-risk novel modalities before committing to full integration. A key example is Roche’s expanded partnership with C4 Therapeutics to develop degrader-antibody conjugates (DACs), structured with $20 million upfront and over $1 billion in total milestone payments, allowing Roche to tap into specialized targeted protein degradation platforms while sharing early-stage research risk.

Concurrently, first-generation ADC pioneers are executing long-term commercial plans to protect their market share and transform into top-tier global oncology powerhouses. Daiichi Sankyo, for instance, unveiled a strategic five-year plan aimed at driving its oncology revenue past $14.6 billion by 2030 and propelling the company into the global top 5 in oncology by 2035. Rather than relying solely on the established success of Enhertu and Datroway, Daiichi’s strategy explicitly focuses on securing "first-in-class" positioning across novel targets, such as B7-H3 (ifinatamab deruxtecan), while using AI and process optimization to streamline manufacturing and discover the next iteration of payload and linker technologies.

The Informatics Layer Behind Every ADC

If there’s a single lesson, it’s that progress now depends on managing complexity rather than avoiding it. A modern ADC program is 3 linked engineering efforts at once, each generating it’s own data, and each meaningful only in relation to the others. The questions that arise in this research are not ones that can be answered from a single dataset; they are answered by integrating biology and chemistry across a program. 

This is precisely the work Karchem Consulting helps to solve. Team KC partners with scientists to configure the platforms that not only hold this data, but hold up to audit as a program advances towards the clinic. Our role is to make sure the systems that record the science are as well-engineered as the molecules themselves. Ready to learn more? Contact us to get the conversation started.